Literature DB >> 11422497

p27 immunostaining is related to prognosis in malignant mesothelioma.

T W Beer1, P Shepherd, N C Pullinger.   

Abstract

AIMS: To evaluate the prognostic value of the proliferation-associated antigen p27 in malignant mesothelioma. METHODS AND
RESULTS: Sections from 36 patients with malignant mesothelioma were immunohistochemically stained for the p27 antigen. The results were quantified by recording the proportion of positively stained nuclei and these data were tested for association with patient survival. p27 expression was also compared with tumour type, MIB-1 expression, apoptotic and mitotic indices. Patients with pleural malignant mesothelioma showing low p27 expression (< 53% of cells positive) survived for significantly shorter periods of time than those with high p27 expression (> or = 53% of cells positive) (P=0.04). The 50% survival time of subjects with low p27 was 4-6 months whereas for those with high p27 expression it was 10-11 months. There was no significant association between p27 expression and MIB-1, apoptotic or mitotic indices.
CONCLUSIONS: Low p27 expression in pleural malignant mesothelioma is associated with a significantly worse prognosis. p27 appears to be an independent prognostic variable which may be of value in counselling patients with malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422497     DOI: 10.1046/j.1365-2559.2001.01136.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.

Authors:  Solange Romagnoli; Ester Fasoli; Valentina Vaira; Monica Falleni; Caterina Pellegrini; Anna Catania; Massimo Roncalli; Antonio Marchetti; Luigi Santambrogio; Guido Coggi; Silvano Bosari
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

2.  Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.

Authors:  A Baldi; D Santini; F Vasaturo; M Santini; G Vicidomini; M Pia Di Marino; V Esposito; A M Groeger; G Liuzzi; B Vincenzi; G Tonini; M Piccoli; F Baldi; S Scarpa
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

Review 3.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

4.  Epidemiology of mesothelioma in Egypt. A ten-year (1998-2007) multicentre study.

Authors:  Yosri Akl; Safy Kaddah; Ahmed Abdelhafeez; Randa Salah; Mohamed Lotayef
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

5.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.